Macquarie wrote in its note that the prohibitions outlined in the Biosecure Act will take effect with respect to these ...

Divis Labs stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from ...

Lauras Labs derives 40% of its revenue from antiretroviral (ARV) drugs, which remain insulated from US tariffs.

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until ...

Gilead delays Biktarvy generics until 2036, boosting its competitive edge and projected stock gains. Read more here.

The pharma stocks are experiencing surge share prices in trade on October 9, 2025 after the White House reportedly mulls over the possibility of not imposing tariffs on generic medicines.

Market watchers attribute the subdued sentiment to factors such as ongoing geopolitical tensions, muted earnings growth, and ...

The NSE Nifty 50 rose 104 points, or 0.41%, to 25,285, after crossing the 25,300 mark during the session. The S&P BSE Sensex ...

Gilead Sciences (GILD) announced on Monday that it has entered into settlement agreements with multiple players to resolve ...

Divi’s Laboratories, Piramal Pharma, Wockhardt, Cipla, Laurus Labs, Aurobindo Pharma, Glenmark Pharmaceuticals, Dr Reddy’s ...

The Act prohibits federal agencies from procuring/contracting with/using biotech equipment or services from companies of concern originating from China ...

On October 1, Nifty Pharma index closed 1.3% higher at 21,733 after falling for seven straight sessions amid steep tariffs by ...